Correspondence
![](https://capedge.com/proxy/CORRESP/0001079973-10-000747/ballard.jpg)
Via EDGAR
United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Attn: Frank Wyman |
AspenBio Pharma, Inc. Form 10-K for the Fiscal Year Ended December 31, 2009 Filed March 9, 2010 Form 10-K/A for the Fiscal Year Ended December 31, 2009 Filed April 28, 2010 File No. 001-33675 |
On behalf of AspenBio Pharma, Inc. (the “Registrant”), we acknowledge receipt of the Staff’s letter, dated June 30, 2010, with comments related to the above-referenced filings.
The Registrant intends to respond to the Staff’s letter by July 30, 2010.
/s/ Mary J. Mullany
Mary J. Mullany
Atlanta | Baltimore | Bethesda | Denver | Las Vegas | Los Angeles | New Jersey | Philadelphia | Phoenix | Salt Lake City | Washington, DC | Wilmington